Literature DB >> 10377152

Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.

A Donohue-Rolfe1, I Kondova, J Mukherjee, K Chios, D Hutto, S Tzipori.   

Abstract

Hemolytic-uremic syndrome (HUS) is a serious disease in children, attributable in the majority of cases to infection with Shiga toxin (Stx)-producing Escherichia coli. Using gnotobiotic piglets orally infected with E. coli O157:H7, which develop Stx-related cerebellar lesions and fatal neurological symptoms, we show that administration of Stx2-specific antiserum well after challenge protected, in a dose-response fashion, against these symptoms for at least 24 h after bacterial challenge. Twenty-six of 30 piglets given Stx2 antiserum survived the challenge, compared to only 4 of 16 animals given control serum or saline. Given our observations in piglets, Stx antibody of human origin may likewise prevent HUS in children.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10377152      PMCID: PMC116557     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

Review 1.  The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome.

Authors:  P M Griffin; R V Tauxe
Journal:  Epidemiol Rev       Date:  1991       Impact factor: 6.222

Review 2.  Mechanisms of action of intravenous immune serum globulin therapy.

Authors:  M Ballow
Journal:  Pediatr Infect Dis J       Date:  1994-09       Impact factor: 2.129

3.  Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.

Authors:  M Bitzan; M Klemt; R Steffens; D E Müller-Wiefel
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

Review 4.  Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action.

Authors:  R I Schiff
Journal:  Pediatr Allergy Immunol       Date:  1994-05       Impact factor: 6.377

5.  The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection.

Authors:  S Tzipori; F Gunzer; M S Donnenberg; L de Montigny; J B Kaper; A Donohue-Rolfe
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: outcome with plasma exchange.

Authors:  A W Roberts; E A Gillett; S J Fleming
Journal:  J Clin Apher       Date:  1991       Impact factor: 2.821

7.  Plasma infusion as treatment for 33 children with haemolytic uraemic syndrome: a good therapy?

Authors:  B Brichard; C Vermylen; M T Heremans; J Ninane; G Cornu
Journal:  Acta Clin Belg       Date:  1993       Impact factor: 1.264

8.  Humoral immune responses to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjects.

Authors:  J S Greatorex; G M Thorne
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

9.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

10.  Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange.

Authors:  A Pereira; R Mazzara; J Monteagudo; C Sanz; L Puig; A Martínez; A Ordinas; R Castillo
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

View more
  17 in total

1.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7.

Authors:  Krystle L Mohawk; Angela R Melton-Celsa; Cory M Robinson; Alison D O'Brien
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

3.  Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.

Authors:  Abhineet S Sheoran; Susan Chapman-Bonofiglio; Barrett R Harvey; Jean Mukherjee; George Georgiou; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.

Authors:  D E Akiyoshi; C M Rich; S O'Sullivan-Murphy; L Richard; J Dilo; A Donohue-Rolfe; A S Sheoran; S Chapman-Bonofiglio; S Tzipori
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

6.  Escherichia coli O157:H7 causes more-severe systemic disease in suckling piglets than in colostrum-deprived neonatal piglets.

Authors:  E A Dean-Nystrom; J F Pohlenz; H W Moon; A D O'Brien
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 7.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Production and characterization of protective human antibodies against Shiga toxin 1.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Differences in virulence among Escherichia coli O157:H7 strains isolated from humans during disease outbreaks and from healthy cattle.

Authors:  Diane R Baker; Rodney A Moxley; Mike B Steele; Jeffrey T Lejeune; Jane Christopher-Hennings; Ding-Geng Chen; Philip R Hardwidge; David H Francis
Journal:  Appl Environ Microbiol       Date:  2007-09-21       Impact factor: 4.792

10.  Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.

Authors:  Abhineet S Sheoran; Susan Chapman; Pradeep Singh; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.